C-Reactive Protein Testing Market Growth Forecast at 4.9% CAGR by Persistence Market Research

The C-reactive protein (CRP) testing market is a rapidly evolving segment of the global diagnostics industry, playing a pivotal role in the early detection, monitoring, and management of various health conditions, especially cardiovascular and inflammatory diseases. According to Persistence Market Research, the market is projected to grow from US$2.85 billion in 2025 to approximately US$3.98 billion by 2032, registering a CAGR of 4.9% during the forecast period.

This growth is fueled by a combination of factors including increasing prevalence of chronic inflammatory disorders, rising adoption of high-sensitivity CRP (hs-CRP) tests, and expanding access to point-of-care (POC) diagnostics. Among product types, the hs-CRP test leads the market, while North America remains the dominant geographical region, holding over 36% market share in 2025 due to its robust diagnostic infrastructure and prevalence of cardiovascular disease.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/22477

Key Highlights from the Report

• The global market is expected to reach US$3.98 Bn by 2032, growing at a CAGR of 4.9%.
• North America is projected to lead with over 36% of market share in 2025.
• The high-sensitivity CRP test will dominate with 42.5% market share.
• Immunoturbidimetry will hold the largest share of assay technology (30%) in 2025.
• Asia Pacific is the fastest-growing region due to rising healthcare investments.
• Rapid POC CRP tests are gaining momentum in antibiotic stewardship initiatives globally.

Market Segmentation
By Test Type and Assay Technology

The CRP testing market is primarily segmented based on test type into standard CRP tests, high-sensitivity CRP (hs-CRP) tests, and point-of-care CRP (POC) tests. The hs-CRP segment is anticipated to hold a leading share due to its pivotal role in cardiovascular risk assessment and preventive care strategies. Meanwhile, POC CRP tests are growing rapidly, especially in primary care and emergency settings, because they offer fast, actionable results without requiring centralized labs.

In terms of assay technology, Immunoturbidimetry remains the most widely used method due to its reliability, affordability, and high-throughput capabilities. It is a standard technique in hospital laboratories and reference labs. On the other hand, Lateral Flow Immunoassay (LFIA) is gaining prominence for its portability and quick result delivery, making it ideal for use in rural clinics, telehealth models, and resource-limited settings.

By End User and Application

CRP testing is utilized across hospitals, diagnostic laboratories, ambulatory surgical centers, and home care settings. Hospitals and diagnostic labs continue to dominate the market due to the volume of testing and infrastructure availability, but the home healthcare segment is witnessing substantial growth owing to rising chronic disease prevalence and the adoption of at-home testing kits.

Application-wise, CRP tests are essential in diagnosing bacterial vs. viral infections, inflammatory diseases like rheumatoid arthritis, cardiovascular conditions, and sepsis. Their inclusion in routine preventive care checkups and antibiotic stewardship programs is further widening their application scope across global healthcare systems.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/c-reactive-protein-testing-market.asp

Regional Insights
North America: Dominating the Global Landscape

North America remains the largest market for CRP testing, driven by a combination of high healthcare expenditure, early technology adoption, and clinical integration of hs-CRP into cardiovascular risk assessment guidelines. In particular, the U.S. benefits from well-established policies, automated platforms, and access to high-sensitivity assays, reinforcing its market leadership.

New developments like Siemens' Atellica CH hs-CRP2 assay and Roche's Tina-quant series enhance diagnostic precision, enabling more effective preventive care strategies. Additionally, strong participation from market leaders and expanding POC testing networks ensure continued market dominance.

Asia Pacific: Fastest-Growing Region

Asia Pacific is the fastest-expanding market due to increasing investments in healthcare infrastructure, growing awareness of chronic diseases, and the government-driven promotion of antimicrobial resistance (AMR) control programs. Countries like China and India are rapidly deploying low-cost CRP POCT solutions, especially in rural and underserved areas.

The region presents opportunities for domestic and international manufacturers, particularly in developing portable CRP testing platforms that align with telehealth and mobile clinic initiatives. As healthcare access improves and diagnostic demand surges, the region is poised for sustained growth.

Market Drivers

A major driver behind the CRP testing market is the rising burden of chronic diseases like rheumatoid arthritis, sepsis, and cardiovascular disease, all of which require repeated CRP level monitoring. The increasing shift toward precision medicine and preventive care also boosts demand for quantitative and hs-CRP testing.

Further, CRP testing is being integrated into antibiotic stewardship initiatives, helping clinicians reduce inappropriate antibiotic use by identifying bacterial infections more effectively. Portable and rapid test kits, especially those using lateral flow immunoassay (LFIA) technology, are gaining ground in emergency departments and primary care, accelerating treatment decisions.

Market Restraints

Despite its advantages, CRP testing faces limitations in specificity, especially in differentiating bacterial from viral infections at lower concentrations. Single-point CRP values may not reflect disease progression accurately unless contextualized with clinical symptoms and CRP kinetics.

Moreover, performance variability across testing platforms, especially among point-of-care and lateral-flow CRP kits, undermines result reliability. The lack of universal reference ranges due to ethnic and demographic variability and limited EHR integration for POCT devices also pose significant challenges to broader adoption.

Market Opportunities

The biggest opportunities lie in integrating CRP testing into telehealth, remote patient monitoring, and home care models. The development of smartphone-enabled lateral flow readers and CRP self-collection kits supports chronic disease management and remote diagnostics, especially in underserved regions.

Furthermore, duplex CRP-procalcitonin tests offer rapid sepsis detection capabilities, vital for emergency and critical care settings. Emerging technologies like microfluidic POC analyzers and CRP-as-a-service models enhance accessibility and open doors to decentralized, scalable diagnostic networks.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/22477

Reasons to Buy the Report

• Offers detailed analysis of current trends, forecasts, and growth opportunities through 2032.
• Provides insights into key market segments such as hs-CRP and point-of-care testing.
• Evaluates leading regional and global players with competitive benchmarking.
• Covers regulatory developments and innovations in CRP assay technologies.
• Enables strategic planning through access to market drivers, restraints, and opportunities.

Frequently Asked Questions (FAQs)

• How Big is the C-Reactive Protein Testing Market?
• What is the Projected Growth Rate of the C-Reactive Protein Testing Market from 2025 to 2032?
• Who are the Key Players in the Global Market for CRP Testing?
• What is the Market Forecast for CRP Testing by 2032?
• Which Region is Estimated to Dominate the Industry through the Forecast Period?

Company Insights

The competitive landscape of the C-reactive protein testing market is led by several key players offering a wide range of automated, high-sensitivity, and point-of-care testing solutions. These companies emphasize research, innovation, and regulatory compliance to strengthen their global presence.

Key Players:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Beckman Coulter, Inc. (Danaher Corporation)
• Thermo Fisher Scientific Inc.
• Randox Laboratories Ltd.
• Ortho Clinical Diagnostics
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories, Inc.
• Horiba, Ltd.
• Sysmex Corporation
• Tosoh Corporation
• DiaSorin S.p.A.
• Merck KGaA
• Becton, Dickinson and Company (BD)
• Abaxis, Inc. (Zoetis)
• Biosystems S.A.
• Genrui Biotech Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Helena Laboratories Corporation

Recent Market Developments:

• Radiometer launched the AQT90 FLEX immunoassay analyzer in May 2024, supporting CRP testing with

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.